MedTrace Logo

Impact of Mortality Salience on Treatment Decisions

NCT06545188 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 746

Last updated 2025-11-24

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if mortality salience has an impact on treatment decisions in urologists and patients with urological cancer. The main questions it aims to answer are:

Does mortality salience lead to more aggressive treatment decisions in a) urologists and b) patients with urological cancer? Which factors predict more aggressive treatment decisions a) in urologists and b) in patients with urological cancer? Is the Fear of cancer recurrence-1 (FCR-1) in German language a valid screening tool for fear of cancer progression in patients with urological cancer?

Researchers will compare a mortality salience trigger to control questions to see if mortality salience leads to more aggressive treatment decisions.

Participants will:

Answer the Mortality Attitudes Personality survey (MAPS) to trigger mortality salience and, in three borderline case vignettes, provide information on how likely they would be to choose a more aggressive therapy.

Conditions

Interventions

OTHER

Mortality Attitudes Personality Survey

Two open questions about death and mortality will bei administered to trigger mortality salience

OTHER

Dental treatment questions (control condition)

Two open questions about a dental treatment (control condition)

Sponsors & Collaborators

  • UHN - Princess Margaret Cancer Centre, Toronto, Canada

    collaborator UNKNOWN

  • Heinrich-Heine University, Duesseldorf

    lead OTHER

Principal Investigators

  • Dominik Fugmann, Dr. med. · Heinrich Heine University Duesseldorf, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-16
Primary Completion
2025-11-08
Completion
2025-11-08

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06545188 on ClinicalTrials.gov